- GPC licenses NeoTherapeutics' satraplatin
- Celgene buys Pharmion for $2.6bn in cash and stock
- GPC Biotech and Pharmion co-develop satraplatin;ends
- Yakult Honsha gets satraplatin rights from GPC
- Schering-Plough, Novacea end Asentar deal
- Algeta completes NOK250mm IPO
- Forest,Paion end stroke collaboration
- Lundbeck gets rights to Paion's Phase III stroke therapeutic
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. firstname.lastname@example.org.
All fields are required.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.